.jpg)
MAFG as a potential therapeutic target to restore chemosensitivity in platinum-resistant cáncer cells
US16/647,368; EP18734266
The present invention relates to the fields of medicine and cancer treatment. The invention more specifically relates to the use of a compound capable of decreasing or inhibiting, in vitro or ex vivo, the expression and/or activity of MAFG and thus increasing ROS-production and chemotherapy sensitivity, specifically in cancer cells resistant to platinum-based therapy. The present disclosure further relates to uses of such compounds, in particular to prepare a pharmaceutical composition to allow or improve the efficiency of a therapy of cancer in a subject in need thereof. The compound of the invention can indeed be advantageously used, in combination with at least one chemotherapeutic drug, for treating cancer, for preventing cancer metastasis, increasing overall survival and/ or for preventing cancer recurrence in a subject. The invention also discloses methods for preventing or treating cancer, cancer metastasis and/or cancer recurrence in a subject, as well as kits suitable for preparing a composition according to the present invention and/or for implementing the herein described methods.
Inventors provide active molecules that allow the physician to prevent or control, preferably decrease, cancer cell proliferation by increasing ROS-production. They are advantageously capable of increasing the effectiveness of chemotherapeutic treatments directed against any cancer. Inventors herein demonstrate that these molecules are in addition capable of reducing the risk of metastasis and/or cancer recurrence.